IRINOTECAN HYDROCHLORIDE TRIHYDRATE
Disclaimer: These predictions are for research purposes only. They do not constitute medical advice and require clinical validation.
Overview
| Property | Value |
|---|---|
| Drug Name | IRINOTECAN HYDROCHLORIDE TRIHYDRATE |
| DrugBank ID | DB00762 |
| HSA Status | Registered with Health Sciences Authority |
| KG Predictions | 41 |
| DL Predictions (≥0.7) | 50 |
Predicted Indications
The following indications are predicted based on TxGNN knowledge graph analysis:
| Indication | Source | Evidence |
|---|---|---|
| hyperlipidemia, familial combined, lpl related | TxGNN Knowledge Graph | L5 |
| obsolete familial combined hyperlipidemia | TxGNN Knowledge Graph | L5 |
| primary mediastinal large b-cell lymphoma | TxGNN Knowledge Graph | L5 |
| primary cutaneous diffuse large b-cell lymphoma, leg type | TxGNN Knowledge Graph | L5 |
| intravascular large b-cell lymphoma | TxGNN Knowledge Graph | L5 |
| langerhans cell histiocytosis | TxGNN Knowledge Graph | L5 |
| t-cell/histiocyte rich large b cell lymphoma | TxGNN Knowledge Graph | L5 |
| rhabdomyosarcoma (disease) | TxGNN Knowledge Graph | L5 |
| leukemia, lymphocytic, susceptibility to | TxGNN Knowledge Graph | L5 |
| lymphoma | TxGNN Knowledge Graph | L5 |
Evidence Summary
External Resources
Generated by SgTxGNN on 2026-03-11